Larimar Therapeutics, Inc. Company profile
About Larimar Therapeutics Inc
Larimar Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing treatments for patients suffering from complex rare diseases using its cell penetrating peptide technology platform. The Company's protein replacement therapy platform is intended to deliver missing proteins inside the machinery of cells to treat devastating rare diseases that is ineffective or no treatments available. Its cell penetrating peptide ( CPP) technology platform, which enables a therapeutic molecule to cross a cell membrane in order to reach intracellular targets that has the potential to enable the treatment of other rare and orphan diseases. The Company's lead product candidate, CTI-1601, is a recombinant fusion protein intended to deliver human frataxin ( FXN), an essential protein to the mitochondria of patients with Friedreich’s ataxia. CTI-1601 is in Phase I clinical program.
Financial summary
BRIEF: For the nine months ended 30 September 2021, Larimar Therapeutics Inc revenues was not reported. Net loss increased 47% to $41.5M. Higher net loss reflects Research and Development increase of 50% to $30.6M (expense), Stock-based Compensation in SGA increase from $709K to $2.5M (expense), Stock-based Compensation in R&D increase from $442K to $1.5M (expense).
Equity composition
Common Stock, $0.001 Par, 06/14, auth. 115M shares,. 20,807,012 issd,. Insiders owns approx. 28.83%.
Latest shares articles
![](https://img.capital.com/imgs/articles/384x2000x0/1350x880_-HP-_Newsquawk-light_1.png)
![Lloyds share price forecast: An attractive dividend stock?](https://img.capital.com/imgs/articles/384x2000x0/Hero-image-bank_1.png)
![Exterior of Infosys headquarters](https://img.capital.com/imgs/articles/384x2000x0/shutterstock_2035197281_0_0.jpg)
![Tesla logo atop of a Tesla Dealership illuminated at night.](https://img.capital.com/imgs/articles/384x2000x0/shutterstock_1494516293_0.jpg)